ECM
AZN icon

Evergreen Capital Management’s AstraZeneca AZN Stock Holding History

Evergreen Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1M Sell
32,180
-923
-3% -$174K 0.11% 178
2026
Q1 		$6.53M Buy
33,103
+582
+2% +$112K 0.14% 155
2025
Q4 		$5.98M Buy
32,521
+10,861
+50% +$1.9M 0.13% 162
2025
Q3 		$3.32M Buy
21,660
+4,924
+29% +$745K 0.08% 218
2025
Q2 		$2.34M Buy
16,736
+4,881
+41% +$684K 0.07% 243
2025
Q1 		$1.74M Buy
11,855
+78
+0.7% +$11.3K 0.06% 268
2024
Q4 		$1.54M Buy
11,777
+928
+9% +$130K 0.05% 289
2024
Q3 		$1.69M Buy
10,849
+733
+7% +$118K 0.06% 273
2024
Q2 		$1.58M Buy
10,116
+635
+7% +$95.6K 0.06% 262
2024
Q1 		$1.28M Buy
9,481
+133
+1% +$17.6K 0.05% 270
2023
Q4 		$1.26M Buy
9,348
+398
+4% +$51.7K 0.05% 271
2023
Q3 		$1.21M Sell
8,950
-417
-4% -$57K 0.05% 268
2023
Q2 		$1.34M Buy
9,367
+827
+10% +$122K 0.06% 254
2023
Q1 		$1.19M Buy
8,540
+232
+3% +$31.2K 0.05% 266
2022
Q4 		$1.13M Buy
8,308
+94
+1% +$11.8K 0.05% 265
2022
Q3 		$901K Buy
8,214
+399
+5% +$50.6K 0.05% 270
2022
Q2 		$1.03M Buy
7,815
+844
+12% +$111K 0.05% 248
2022
Q1 		$925K Buy
6,971
+902
+15% +$108K 0.04% 292
2021
Q4 		$707K Buy
6,069
+990
+19% +$116K 0.03% 327
2021
Q3 		$610K Buy
5,079
+882
+21% +$103K 0.03% 334
2021
Q2 		$503K Buy
4,197
+747
+22% +$82K 0.02% 339
2021
Q1 		$343K Buy
3,450
+1,080
+46% +$109K 0.02% 368
2020
Q4 		$237K Buy
2,370
+71
+3% +$7.52K 0.01% 385
2020
Q3 		$252K Buy
2,299
+202
+10% +$22.5K 0.02% 349
2020
Q2 		$222K Buy
+2,097
New +$217K 0.02% 345
2020
Q1 		– Sell
-2,588
Closed -$258K – 388
2019
Q4 		$258K Buy
2,588
+136
+6% +$12.8K 0.02% 372
2019
Q3 		$219K Buy
+2,452
New +$213K 0.02% 376
2019
Q1 		– Sell
-3,570
Closed -$271K – 409
2018
Q4 		$271K Buy
+3,570
New +$279K 0.03% 288

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Evergreen Capital Management's AZN Position: Q2 2026 in Review

Evergreen Capital Management reduced its AstraZeneca (AZN) stake by 2.8% in Q2 2026, selling an estimated $174K and leaving 32,180 shares worth $6.1M. The position accounts for 0.11% of the portfolio, ranked #178.

Evergreen Capital Management first reported a position in AZN in Q4 2018 and has held it in 28 quarters since. The position peaked at $6.53M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Evergreen Capital Management held 32,180 shares of AstraZeneca worth $6.1M as of Q2 2026.
  • Evergreen Capital Management sold 923 AstraZeneca shares in Q2 2026, an estimated $174K.
  • AstraZeneca made up 0.11% of Evergreen Capital Management's portfolio in Q2 2026, its #178 holding.
  • Evergreen Capital Management first reported a position in AstraZeneca in Q4 2018 and has held it in 28 quarters since.
  • Evergreen Capital Management's AstraZeneca position peaked at $6.53M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.